Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Tomohiro Kurokawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7932-8724; OpenAlex author ID A5027044231. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Exocrine Pancreatic Insufficiency May Provide Important Clinical Context for Nutritional Risk in Pancreatic Cancer. First author DOI 10.1093/nutrit/nuag110↗
  2. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  3. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02414-9↗
  4. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  5. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000697↗
  6. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Co-author DOI 10.1111/cas.12888↗
  7. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Co-author DOI 10.1038/bjc.2014.49↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taneomi KUROKAWA · 1 shared paper, 2026 · strength 0.63
  2. Soldano Ferrone · 2 shared papers, 2020–2021 · strength 0.19
  3. David Tsai Ting · 2 shared papers, 2019–2021 · strength 0.16
  4. Theodore Sunki Hong · 2 shared papers, 2019–2021 · strength 0.16
  5. Carlos Fernández-del Castillo · 2 shared papers, 2019–2021 · strength 0.16
  6. Azfar Neyaz · 2 shared papers, 2019–2021 · strength 0.16
  7. Vikram Deshpande · 2 shared papers, 2019–2021 · strength 0.16
  8. David P. Ryan · 2 shared papers, 2019–2021 · strength 0.16
  9. Cristina R. Ferrone · 2 shared papers, 2019–2020 · strength 0.16
  10. Andrew Scott Liss · 2 shared papers, 2019–2020 · strength 0.16
  11. Tatsuya Oda · 3 shared papers, 2014–2017 · strength 0.16
  12. Yusuke Ohara · 3 shared papers, 2014–2017 · strength 0.16
  13. Tsuyoshi Enomoto · 3 shared papers, 2014–2017 · strength 0.16
  14. Yoshimasa Akashi · 3 shared papers, 2014–2017 · strength 0.16
  15. Ryoichi Miyamoto · 3 shared papers, 2014–2017 · strength 0.16
  16. Nobuhiro Ohkohchi · 3 shared papers, 2014–2017 · strength 0.16
  17. Andrew Louis Warshaw · 1 shared paper, 2021 · strength 0.10
  18. Lei Cai · 1 shared paper, 2021 · strength 0.10
  19. Theodoros P. Michelakos · 1 shared paper, 2021 · strength 0.10
  20. Motaz Qadan · 1 shared paper, 2021 · strength 0.10
  21. Cristina Rosa Ferrone · 1 shared paper, 2021 · strength 0.10
  22. Jennifer Yon-Li Wo · 1 shared paper, 2021 · strength 0.10
  23. Keith D. Lillemoe · 1 shared paper, 2021 · strength 0.10
  24. Colin D. Weekes · 1 shared paper, 2021 · strength 0.10
  25. Jane J. Cheng · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.